Lung cancer drug shows promise against brain metastases
NCT ID NCT04563871
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug osimertinib (Tagrisso) in 73 patients with a specific type of lung cancer that had spread to the lining of the brain and spinal cord (leptomeningeal metastases). Patients took one 80 mg tablet daily. The goal was to see if the drug could improve overall survival and control the spread of cancer in this hard-to-treat area.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib (Tagrisso) 80 mg tablet taken once daily
What this could lead to
If successful, this could provide an effective treatment option for lung cancer patients whose disease has spread to the brain and spinal cord lining, potentially extending survival.
What could go wrong
This is a single-arm Phase II study with no comparison group, so results may be less definitive. The drug may not work for all patients and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
ChungBuk National University Hospital
Cheonju, South Korea
-
National Cancer Center
Goyang, South Korea
-
Samsung Medical Center
Seoul, 135-710, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea